THE ULTIMATE K-BEAUTY LIFTING CREAM FOR MOTHER'S DAY: DISCOVER THE POWER OF BIOHEAL BOH
Shop now on Amazon and Olive Young Global —limited-time offers through May
SEOUL, South Korea , May 9, 2025 /PRNewswire/ -- This Mother's Day, treat your loved ones or yourself to the gift of radiant, youthful skin with BIOHEAL BOH's signature Probioderm 3D Lifting collection.
Created by CJ Olive Young, Korea's No.1 beauty and health retailer, this bestselling anti-aging line featuring the hero 3D Lifting Cream and the innovative 3D Lifting Cream Mist is now available at unbeatable discounts on Amazon U.S. and the Olive Young Global app/website.
- Amazon (U.S. Only): Enjoy up to 40% off from May 7 to May 13 (PST)
- Olive Young Global (international shipping): Enjoy up to 50% off from May 1 to May 15 (KST)
Developed with a focus on strengthening the skin barrier and enhancing elasticity through a potent blend of probiotics and peptides, the Probioderm collection offers visible results.
Featured Products:
BIOHEAL BOH Probioderm 3D Lifting Cream 1.7 fl oz
This rich cream absorbs quickly into dry skin, delivering intensive nourishment overnight while visibly firming the skin.
- Infused with 17 types of peptides to improve skin elasticity
- Designed for both face and neck use
- May experience noticeable lifting results within two weeks
- Loved by beauty fans for its firming, "purple-lifting" effect (no injections needed!)
- Available at: Amazon and Olive Young Global
BIOHEAL BOH Probioderm 3D Lifting Cream Mist 3.38 fl oz
An innovative mist that transforms from cream to spray for easy, on-the-go lifting care.
- Delivers long-lasting hydration and glow
- Perfect for hydration boosts anytime, anywhere
- Available at: Amazon and Olive Young Global
BIOHEAL BOH Probioderm 3D Lifting Full Face Tension Gel Mask
A hydrogel sheet mask designed to deliver an instant lifting effect, focusing on the jawline and forehead.
- PDRN helps revitalize the skin and improve the appearance of fine lines
- 20 types of peptides boost skin firmness and elasticity
- Available at: Amazon and Olive Young Global
BIOHEAL BOH Probioderm 3D Lifting Ampoule 1.01 fl oz
A lightweight yet powerful ampoule formulated for daily use on all skin types.
- Features 17 types of peptides for enhanced skin resilience and elasticity
- Comfortable wear throughout the day
- Available at: Amazon and Olive Young Global
This Mother's Day, experience the transformative power of K-beauty innovation with Olive Young's most beloved anti-aging skincare and share the gift of glow with those who deserve it most.
About CJ Olive Young
CJ Olive Young, established in 1999, is South Korea's leading beauty and health retailer. Our brand name, "Olive Young," embodies the philosophy of "All Live Young," reflecting our vision for everyone to live a healthy and beautiful life at all times. Through its flagship store, "Olive Young," it offers trendy and radiant K-beauty products to customers worldwide. With over 1,370 stores, more than 20 years of expertise, data-driven insights, and strong partnerships, Olive Young curates a distinguished selection of K-beauty and wellness products. As a subsidiary of CJ Group, a global lifestyle company, CJ Olive Young continues to lead the industry by delivering the value of healthy beauty to customers worldwide. For more information, visit global.oliveyoung.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
04-06-2025
- Korea Herald
G-Dragon, Le Sserafim, Babymonster push on with overseas concerts amid COVID-19 surge in Asia
K-pop companies refrain from cancellations as no official restrictions are in place Despite the recent surge in the number of COVID-19 cases across parts of Asia, K-pop stars, including G-Dragon, Le Sserafim and Babymonster, are pressing ahead with their overseas concerts. According to the Korea Disease Control and Prevention Agency (KDCA) on Monday, countries including China, Thailand and Singapore have recently reported a notable increase in COVID-19 cases. While the situation in Korea remains relatively stable, the agency warned that a summer resurgence is possible due to international travel and regional outbreaks. The NB.1.8.1 variant — now dominant in the affected countries — is known for its strong transmissibility and immune-evasive properties, although its severity and fatality rate remain relatively low. The KDCA is advising high-risk travelers to these countries to get vaccinated before departure. G-Dragon of Big Bang is currently on his 'Ubermensch' world tour, performing across nine Asian cities including Taipei, Kuala Lumpur, Jakarta, Hong Kong and Bangkok as well as Sydney and Melbourne in Australia. He is slated to perform in Macao for three concerts starting June 7. Asked whether shows in Southeast Asia might be canceled due to COVID-19 concerns, his agency Galaxy Corporation told The Korea Herald, 'We don't know at this point.' G-Dragon recently called off his "G-Dragon Media Exhibition: Ubermensch" in Shanghai, which was originally scheduled to run from May 30 to June 22. While the agency cited 'unforeseen circumstances beyond our control' as the reason for the cancellation, the uptick in COVID-19 cases in China is widely suspected as a contributing factor. Babymonster, also on an Asia tour, wrapped up its 'Hello Monsters' concerts in Singapore and Hong Kong in May and is preparing for its final Southeast Asian stop in Bangkok from June 7-8. YG Entertainment confirmed it has no plans to postpone or cancel the shows. 'We're monitoring the situation closely, but the outbreak is limited to certain regions. Everything is proceeding as planned,' a YG official told The Korea Herald on Wednesday. Le Sserafim is scheduled to perform in Taiwan and Hong Kong in July, followed by concerts in the Philippines, Thailand and Singapore in August as part of its 'Easy Crazy Hot' world tour. Source Music's parent company, Hybe, also confirmed that all shows will proceed as scheduled. JYP Entertainment's acts — Niziu, Nmixx and Xdinary Heroes — are also expected to hold small-scale performances in Hong Kong, Macao and Taiwan, respectively, in the second half of the year, with no changes announced. An industry official noted that unless governments issue specific warnings or event restrictions, K-pop agencies are unlikely to take unilateral action regarding concert postponements. 'There aren't any government guidelines like we saw during the height of the pandemic, so it's hard for companies to take preemptive action on their own,' one agency source said. Another industry official echoed the sentiment: 'Without national-level advisories, it's difficult for agencies to make those decisions independently.'
Korea Herald
31-05-2025
- Korea Herald
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme "Empowering the Potential of ctDNA-MRD," 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. "While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology." "K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact'' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. "This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region'' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: K-CONNECT NEXT LANDMARK Session Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
Korea Herald
16-05-2025
- Korea Herald
Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan
NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions, a leader in prenatal and oncology genetic testing, and NEWCL Biomedical Laboratory, Taiwan's pioneering clinical laboratory with LDTs certification, have joined forces to establish an advanced Next-Generation Sequencing (NGS) laboratory in Taiwan. This collaboration was sealed with the signing of a Memorandum of Understanding (MoU) at NEWCL's state-of-the-art facility in New Taipei City. Gene Solutions is set to bring its cutting-edge NIPT tests (trademarked as triSure™) and oncology tests (SPOT-MAS early cancer detection, K-TRACK, K-4CARE comprehensive genomic profiling, ctDNA-MRD monitoring) to Taiwan, expanding its footprint in the APAC region. These innovative tests, trusted by millions across Asia, will soon be available to Taiwanese patients, offering unparalleled accuracy and reliability. NEWCL, established in 2012 and part of DITECH Enterprise, is a premier biomedical laboratory located in New Taipei City. It serves major hospitals and medical service units across Taiwan, providing a wide range of bio testing services including HBV, HCV, Genotype, and Allergen Chip testing. Combining Gene Solutions' expertise in NGS test development with NEWCL's robust laboratory capabilities, this partnership aims to create one of Taiwan's most advanced NGS laboratories. This facility will cater to the growing demand for sophisticated DNA testing in prenatal care and precision oncology, ensuring Taiwanese patients have access to the latest advancements in genetic testing. With the anticipated launch of the partnered NGS lab and tech-transfer in 2025, both companies will explore the commercialization of NGS testing in Taiwan through NEWCL's established commercial network, including TUNG-BO Medical Ltd. Gene Solutions, with its strong foundation in Molecular Biology Research and Genetic Counseling, will drive scientific conferences, medical training, and research collaborations with hospitals and medical service units across Taiwan. In prenatal care, Gene Solutions plans to integrate its unique carrier screening (mother recessive genes) and single-gene screening (de-novo mutations of the fetus) into renowned Non-invasive Prenatal Testing (NIPT). This innovative approach has already proven successful in Southeast Asia, where over one million pregnant women have benefited from triSure tests. In oncology, the collaboration aims to bring Gene Solutions' latest Comprehensive Genomic, Transcriptomic Profiling and ctDNA Molecular Residual Disease tests K-TRACK, K-4CARE to Taiwanese medical oncologists. Currently, samples for such advanced tests must be sent overseas, which is costly and time-consuming. This partnership will eliminate these barriers, providing faster and more cost-effective solutions for cancer patients in Taiwan. Furthermore, with the commitment from NEWCL and Gene Solutions to the scientific community, oncology researchers in Taiwan will have enhanced opportunities to explore novel therapeutic biomarkers for precision oncology. Dr. Nguyen Hoai Nghia, Co-founder and CEO of Gene Solutions, expressed his enthusiasm: "We are excited to collaborate with leading partners in Asia to accelerate the adoption of cutting-edge precision healthcare technology. NEWCL's expertise in laboratory operations and DITECH's market experience will be invaluable in making these advancements accessible in Taiwan." Ms. Ku, Chi-Ming, Director of NEWCL Biomedical Laboratory, also shared: "NEWCL is thrilled to partner with Gene Solutions to bring the most advanced NGS applications to Taiwan. This collaboration marks a significant milestone in our mission to provide cutting-edge genetic testing services. By combining our laboratory excellence with Gene Solutions' innovation in prenatal and oncology diagnostics, we are poised to transform the landscape of precision medicine for patients across Taiwan." This strategic partnership is poised to transform precision healthcare in Taiwan, bringing hope and advanced solutions to patients and healthcare providers alike. About Gene Solutions Gene Solutions, a multinational biotech company, offers a comprehensive genetic testing portfolio utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence algorithms. The testing services include cell-free DNA non-invasive prenatal testing (NIPT), circulating tumor DNA (ctDNA) cancer screening, genomic profiling, and treatment monitoring. Established in 2017, Gene Solutions operates a network of seven NGS laboratories, including two central CAP-accredited laboratories in Singapore and Vietnam. With over two million tests provided to patients, we remain committed to delivering accessible genetic testing services to more than 4,500 hospitals and clinics across Asia. To learn more about Gene Solutions, please visit
